Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cline Mining soars 66%: Canadian market movers

Elizabeth Walters Elizabeth Walters, Stockhouse
0 Comments| January 24, 2013

{{labelSign}}  Favorites
{{errorMessage}}

On Tuesday, the top TSX mover was Research In Motion Ltd. (TSX: T.RIM, Stock Forum). The stock was up 4.45% and was trading at $18.07 on volume of 12.9 million. On Jan. 23, the wireless innovator said that its new Enterprise Mobility Management solution, BlackBerry Enterprise Service 10, is now available for download.

The BlackBerry Enterprise Service 10 offers mobile device management, mobile application management and secure mobile connectivity, and delivers a cost-efficient and reliable solution for business customers.

Cline Mining Corp. (TSX: T.CMK, Stock Forum) was the second most active stock on the TSX. It rocketed 66.67% and was trading at $0.15 on volume of 8.4 million shares. On Jan. 22, the coal coal-focused company said it retained GMP Securities L.P. as its exclusive financial advisor.

With the assistance of GMP, the company is in the process of soliciting proposals for possible alternative transactions with a view to maximizing value for the company and its stakeholders.

Med BioGene Inc. (TSX: V.MBI, Stock Forum) was the volume leader on the TSX Venture Exchange. It soared 60% and was trading at $0.08 on volume of 4.8 million. On Jan. 23, the science-based company announced that Precision Therapeutics has successfully completed their previously announced clinical studies to validate the use of LungExpress Dx with tissue preserved by RNAlater, a molecular fixative.

On April 15, 2011, Precision and Med BioGene closed their commercialization, license and research reimbursement agreement. The agreement provides to Precision exclusive global rights to develop and commercialize LungExpress Dx.

The second most active stock on the TSX Venture was Alexander Energy (TSX: V.ALX, Stock Forum). It rose 11.76% and was trading at $0.19 after 3.7 million shares changed hands. On Jan. 14, the oil and gas company said that December 2012 exit production averaged 929 barrels of oil per day, at 48% oil, an increase of 263 barrels of oil per day.



{{labelSign}}  Favorites
{{errorMessage}}